Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
NCT01874431
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
823
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetic Nephropathies
Interventions
DRUG:
Finerenone (BAY94-8862)
DRUG:
Placebo
Sponsor
Bayer